Calcified aortic valve disease
Conditions
Interventions
two sets:none
Sponsors
Tianjin Chest Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: A. Patients diagnosed with moderate or above aortic stenosis (accompanied by mild aortic insufficiency) requiring surgical aortic valve replacement were included in the experimental group. The severity of aortic valve stenosis was classified according to the American college of cardiology and American heart association (ACC/AHA) 2014 guidelines for the management of patients with valvular heart disease. The diagnostic conditions included: (1) mild aortic valve stenosis: aortic Vmax 2.0-2.9m/s or average ?P1.5cm2; (2) Moderate aortic stenosis: aortic Vmax 3.0-3.9m/s or average P 20-39 MMHG or valve area 1.0-1.5cm2; (3) Severe aortic stenosis: aortic Vmax=4m/s or average ?P=40mmHg or valve area ?1.0cm2. Diagnosis and confirmation of aortic valve calcification: Ultrasound suggests one or more punctate or annular echo-enhancement of the aortic valve with a diameter of more than 1mm. Diagnosis and diagnosis of calcified aortic stenosis: moderate aortic stenosis, moderate to severe aortic stenosis, severe aortic stenosis, valve area =1.5cm2, and cross-valve flow rate =2.5 m/s. B. When normal aortic valve tissue specimens were selected, the aortic valves of patients who underwent Bentall or Bentall+Suns surgery due to acute type A aortic dissection at the same period were included in the control group after pathological examination and the valve tissue was basically normal.
Exclusion criteria
Exclusion criteria: Exclusion criteria: A. Rheumatic aortic stenosis, infectious endocarditis or inflammatory valvular disease, congenital bicuspid aortic valve disease. B. Patients with moderate to severe aortic valve insufficiency; Aortic stenosis with mitral valve disease. C. Patients with heart failure (grade IV cardiac function), myocardial infarction, active myocarditis, acute myocardial injury, aortic dissection, pulmonary embolism, silicosis, asthma, malignant tumor and other diseases. D. Patients with acute or chronic inflammatory diseases caused by bacterial or fungal or viral infections. E. Patients with chronic diseases of abnormal immune function (such as blood diseases, autoimmune diseases, immune deficiency, hyperthyroidism, hypothyroidism, parathyroid disease, rheumatoid arthritis, inflammatory bowel disease, etc.) who have received initial treatment or have received treatment. F. Other reasons may lead to immune function or metabolic abnormalities (such as infectious diseases, fever temperature >37.4?, abnormal liver and kidney function, gout, etc.). G. Restenosis after aortic valve replacement. H. Have taken antibiotics, immunosuppressants, steroids, or nsaids within the past 3 months, and have a history of surgery or trauma within 3 months. I. Used hydroxymethylglutaryl-coenzyme A (HMG-CO A) reductase inhibitor (statins) within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Long non-coding RNA; | — |
Countries
China
Contacts
Public ContactChang Chao
Tianjin Chest Hospital
Outcome results
None listed